by Vishnu Priyan for Pharmaceutical Technology
“Windtree Therapeutics and Lee’s Pharmaceutical have signed a licence agreement to develop and market the former’s istaroxime for acute heart failure and cardiogenic shock in Greater China.
Lee’s will also gain rights for Windtree’s preclinical next-generation sarco/endoplasmic reticulum Ca2+ATPase (SERCA2a) activators and a Phase II hypertension drug, rostafuroxin.
Windtree will receive $138.1m in milestone payments and royalty payments on product sales.
Almost $100m is earmarked for the assets to treat heart failure.
Lee’s Pharmaceutical will fund the complete development, production regulatory and commercial expenditure linked to the products in the licensed territory…”
Continue reading at the original source, linked here.
